Efficacy
FTD/TPI treatment was associated with a median (95% CI) PFS of 2.8 (2.7–3.0) months in the overall population. Median PFS increased with increasing durations of FTD/TPI treatment, from 2.2 (2.0–2.3) months in the group completing 0–3 cycles to 9.4 (8.7–10.5) months in the group completing ≥8 cycles (Fig. Median progression-free survival by duration of FTD/TPI treatment. CI, confidence interval. FTD/TPI, trifluridine/tipiracil. PFS, progression-free survivalORR was 2.1% (95% CI 1.3–3.2) in the PRECONNECT population, while DCR was 33.3% (95% CI 30.2–36.4). ORR increased with longer durations of FTD/TPI treatment: 0.6% (95% CI 0.2–1.6), 4.6% (95% CI 2.2–8.2) and 7.9% (95% CI 2.6–17.6) with 0–3, 4–7 and ≥ 8 cycles, respectively. DCR increased with longer durations of FTD/TPI treatment: 12.3% (95% CI 9.9–15.2), 75.3% (95% CI 69.1–80.9), and 96.8% (95% CI 89.0–99.6), with 0–3, 4–7 and ≥ 8 cycles, respectively.